Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 2/2017

03.02.2017 | ORIGINAL ARTICLE

The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage

verfasst von: Augustas Beiša, Mindaugas Kvietkauskas, Virgilijus Beiša, Mindaugas Stoškus, Elvyra Ostanevičiūtė, Eugenijus Jasiūnas, Laimonas Griškevičius, Kęstutis Strupas

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to determine the utility of the Bethesda category and its association with BRAF mutation in prediction of the papillary thyroid cancer (PTC) stage.

Methods

A prospective study analyzed patients who had ultrasound-suspicious thyroid nodules, underwent FNA and cytological examination, and were classified according to the Bethesda system. Patients from Undetermined Significance Or Follicular Lesion Of Undetermined Significance (AUS/FLUS), Follicular Neoplasm or Suspicious for a Follicular Neoplasm (FN/SFN), Suspicious for Malignant Cells (SMC), and Positive for Malignant Cells (PMC) groups were examined for the BRAF mutation and had a thyroid surgery. Demographical and histological features and stage of the disease were evaluated for PTC patients in accordance with the Bethesda category and its association with BRAF mutation.

Results

Three hundred eight of all patients underwent operation. One hundred forty-three (46.4%) of them were diagnosed with PTC. In 14 (9.8%) PTC cases, FNA biopsies were classified as AUS/FLUS, 23 (16.1%) as FN/SFN, 41 (28.7%) as SMC, and 65 (45.5%) as PMC. I–II stages of PTC were diagnosed for 88 (61.5%) patients and III–IVA for 55 (38.5%). Patients from the SMC and PMC groups had larger tumors, higher incidence of lymph node metastases, classical PTC type, B-type Raf (BRAF) positive, and III–IVA stage cancer, than patients from the AUS/FLUS and FN/SFN groups. When comparing 27 (18.9%) BRAF-negative patients from the AUS/FLUS and FN/SFN groups with 116 (81.1%) BRAF-negative patients from the SMC and PMC groups and all BRAF-positive patients, the prediction of more aggressive histological features and stage was slightly improved.

Conclusions

Higher Bethesda categories are associated with higher stages of PTC. Association of the Bethesda category with BRAF mutation can slightly improve the value of stage prediction.
Literatur
1.
Zurück zum Zitat Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787–803. doi:10.1530/eje.1.02158 CrossRefPubMed Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154(6):787–803. doi:10.​1530/​eje.​1.​02158 CrossRefPubMed
3.
Zurück zum Zitat Lukas J, Drabek J, Lukas D, Dusek L, Gatek J (2013) The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157:266–275. doi:10.5507/bp.2012.086 PubMed Lukas J, Drabek J, Lukas D, Dusek L, Gatek J (2013) The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 157:266–275. doi:10.​5507/​bp.​2012.​086 PubMed
5.
Zurück zum Zitat Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT (2015) VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch 467:155–168. doi:10.1007/s00428-015-1773-0 CrossRefPubMed Na JI, Kim JH, Kim HJ, Kim HK, Moon KS, Lee JS, Lee JH, Lee KH, Park JT (2015) VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch 467:155–168. doi:10.​1007/​s00428-015-1773-0 CrossRefPubMed
6.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. doi:10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. doi:10.​1089/​thy.​2015.​0020 CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K (2016) The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynol Pol 67:35–40. doi:10.5603/EP.2016.0005 CrossRefPubMed Beiša A, Beiša V, Stoškus M, Ostanevičiūtė E, Griškevičius L, Strupas K (2016) The value of the repeated examination of BRAF V600E mutation status in diagnostics of papillary thyroid cancer. Endokrynol Pol 67:35–40. doi:10.​5603/​EP.​2016.​0005 CrossRefPubMed
9.
Zurück zum Zitat Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM (2015) Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: new insights. Cancer Cytopathol 123:593–602. doi:10.1002/cncy.21586 CrossRefPubMed Rossi ED, Martini M, Bizzarro T, Capodimonti S, Cenci T, Lombardi CP, Pontecorvi A, Fadda G, Larocca LM (2015) Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: new insights. Cancer Cytopathol 123:593–602. doi:10.​1002/​cncy.​21586 CrossRefPubMed
10.
12.
Zurück zum Zitat Fnais N, Soobiah C, Al-Qahtani K, Hamid JS, Perrier L, Straus SE, Tricco AC (2015) Diagnostic value of fine needle aspiration BRAF (V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol 46:1443–1454. doi:10.1016/j.humpath.2015.06.001 CrossRefPubMed Fnais N, Soobiah C, Al-Qahtani K, Hamid JS, Perrier L, Straus SE, Tricco AC (2015) Diagnostic value of fine needle aspiration BRAF (V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. Hum Pathol 46:1443–1454. doi:10.​1016/​j.​humpath.​2015.​06.​001 CrossRefPubMed
14.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. (2010) AJCC Cancer staging manual. 7th ed. Springer-Verlag New York. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A et al. (2010) AJCC Cancer staging manual. 7th ed. Springer-Verlag New York.
15.
Zurück zum Zitat Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS (2015) Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery 158:1500–1511. doi:10.1016/j.surg.2015.05.016 CrossRefPubMed Kim SK, Woo JW, Lee JH, Park I, Choe JH, Kim JH, Kim JS (2015) Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. Surgery 158:1500–1511. doi:10.​1016/​j.​surg.​2015.​05.​016 CrossRefPubMed
17.
Zurück zum Zitat Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z (2015) Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens. Tumour Biol 4 Meng Z, Lu J, Wu H, Zhao Y, Luo Y, Gao J, Zhu Q, Jiang Y, Li W, Liang Z (2015) Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens. Tumour Biol 4
18.
Zurück zum Zitat Ali SZ, Cibas ES (2010) The Bethesda system for reporting thyroid cytopathology: definitions, criteria and explanatory notes, 1st edn. Springer-Verlag New York, LLC, New York. doi:10.1007/978-0-387-87666-5 CrossRef Ali SZ, Cibas ES (2010) The Bethesda system for reporting thyroid cytopathology: definitions, criteria and explanatory notes, 1st edn. Springer-Verlag New York, LLC, New York. doi:10.​1007/​978-0-387-87666-5 CrossRef
21.
Zurück zum Zitat Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092–2098. doi:10.1210/jc.2009-0247 CrossRefPubMed Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN (2009) Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 94:2092–2098. doi:10.​1210/​jc.​2009-0247 CrossRefPubMed
22.
Zurück zum Zitat VanderLaan PA, Marqusee E, Krane JF (2012) Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda system for reporting thyroid cytopathology. Cancer Cytopathol 120:245–253. doi:10.1002/cncy.21189 CrossRefPubMedPubMedCentral VanderLaan PA, Marqusee E, Krane JF (2012) Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda system for reporting thyroid cytopathology. Cancer Cytopathol 120:245–253. doi:10.​1002/​cncy.​21189 CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Galuppini F, Pennelli G, Vianello F, Censi S, Zambonin L, Watutantrige-Fernando S, Manso J, Nacamulli D, Lora O, Pelizzo MR, Rugge M, Barollo S, Mian C (2016) BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clin Chem Lab Med 54(9):1531–1539. doi:10.1515/cclm-2015-0218 PubMed Galuppini F, Pennelli G, Vianello F, Censi S, Zambonin L, Watutantrige-Fernando S, Manso J, Nacamulli D, Lora O, Pelizzo MR, Rugge M, Barollo S, Mian C (2016) BRAF analysis before surgery for papillary thyroid carcinoma: correlation with clinicopathological features and prognosis in a single-institution prospective experience. Clin Chem Lab Med 54(9):1531–1539. doi:10.​1515/​cclm-2015-0218 PubMed
26.
Zurück zum Zitat Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27(18):2977–2982. doi:10.1200/jco.2008.20.1426 CrossRefPubMedPubMedCentral Xing M, Clark D, Guan H, Ji M, Dackiw A, Carson KA, Kim M, Tufaro A, Ladenson P, Zeiger M, Tufano R (2009) BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol 27(18):2977–2982. doi:10.​1200/​jco.​2008.​20.​1426 CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89–97CrossRefPubMed Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, Yabuta T, Fukushima M, Inoue H, Tomoda C, Kihara M, Uruno T, Higashiyama T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Miyauchi A (2009) BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J 56(1):89–97CrossRefPubMed
Metadaten
Titel
The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage
verfasst von
Augustas Beiša
Mindaugas Kvietkauskas
Virgilijus Beiša
Mindaugas Stoškus
Elvyra Ostanevičiūtė
Eugenijus Jasiūnas
Laimonas Griškevičius
Kęstutis Strupas
Publikationsdatum
03.02.2017
Verlag
Springer Berlin Heidelberg
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 2/2017
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-017-1560-2

Weitere Artikel der Ausgabe 2/2017

Langenbeck's Archives of Surgery 2/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.